Greenwood Capital Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Greenwood Capital Associates’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.65M	Buy	13,873 +2,612	+23%	+$1.78M	0.85%	30
2026 Q1	$8.7M	Sell	11,261 -267	-2%	-$204K	0.96%	27
2025 Q4	$8.9M	Sell	11,528 -1,063	-8%	-$722K	0.97%	26
2025 Q3	$7.08M	Sell	12,591 -270	-2%	-$153K	0.82%	40
2025 Q2	$6.75M	Buy	12,861 +4,419	+52%	+$2.47M	0.84%	32
2025 Q1	$5.35M	Buy	+8,442	New	+$5.81M	0.72%	48
2020 Q4	–	Sell	-5,629	Closed	-$3.15M	–	211
2020 Q3	$3.15M	Sell	5,629 -70	-1%	-$42.4K	0.61%	55
2020 Q2	$3.55M	Sell	5,699 -3,867	-40%	-$2.19M	0.81%	47
2020 Q1	$4.67M	Buy	+9,566	New	+$3.95M	1.37%	29
2019 Q2	–	Sell	-14,138	Closed	-$5.8M	–	197
2019 Q1	$5.8M	Buy	14,138 +956	+7%	+$394K	1.49%	23
2018 Q4	$4.92M	Buy	+13,182	New	+$4.82M	1.29%	31

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Greenwood Capital Associates's REGN Position: Q2 2026 in Review

Greenwood Capital Associates increased its Regeneron Pharmaceuticals (REGN) stake by 23% in Q2 2026, buying an estimated $1.78M and bringing the position to 13,873 shares worth $8.65M. The position accounts for 0.85% of the portfolio, ranked #30.

Greenwood Capital Associates first reported a position in REGN in Q4 2018 and has held it in 11 quarters since. The position peaked at $8.9M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Greenwood Capital Associates held 13,873 shares of Regeneron Pharmaceuticals worth $8.65M as of Q2 2026.
Greenwood Capital Associates bought 2,612 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.78M.
Regeneron Pharmaceuticals made up 0.85% of Greenwood Capital Associates's portfolio in Q2 2026, its #30 holding.
Greenwood Capital Associates first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
Greenwood Capital Associates's Regeneron Pharmaceuticals position peaked at $8.9M in Q4 2025.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.